Thrombinn.凝血酶
Rivaroxabann.利伐沙班
Heartfailureisassociatedwithactivationofthrombin-relatedpathways,whichpredictsapoorprognosis.IntheCOMMANDERHFTrial,patientswhohadchronicheartfailure,aleftventricularejectionfractionof40%orless,coronaryarterydisease,andelevatedplasmaconcentrationsofnatriureticpeptidesandwhodidnothaveatrialfibrillationwererandomlyassignedtoreceiverivaroxabanatadoseof2.5mgtwicedailyorplaceboinadditiontostandardcareaftertreatmentforanepisodeofworseningheartfailure.Overamedianfollow-upperiodof21.1months,theprimaryendpointofdeathfromanycause,myocardialinfarction,orstrokeoccurredin25.0%patientsofrivaroxabanand26.2%patientsofplacebo.Nosignificantdifferenceinall-causemortalitywasnotedbetweentherivaroxabangroupandtheplacebogroup(21.8%and22.1%,respectively).Theprincipalsafetyout
